Clinical Trial Update: Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2A study of TRC253, an androgen receptor antagonist, in metastatic castration-resistant prostate cancer completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• TRC253 (TRC253)

Snippet

Sponsor: Tracon Pharmaceuticals Inc. | Conditions: Metastatic Castrate-resistant Prostate Cancer, Adenocarcinoma, Prostate | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-04-23